Rotavirus Infections - Pipeline Review, H1 2015

05:00 EDT 8 Jun 2015 | BioPortfolio Reports

Recently added to the BioPortfolio report store, Rotavirus Infections - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-04-28. This 55-page report is available in PDF from $2000.

Rotavirus Infections - Pipeline Review, H1 2015


Global Markets Direct’s, ‘Rotavirus Infections - Pipeline Review, H1 2015’, provides an overview of the Rotavirus Infections’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Rotavirus Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rotavirus Infections and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- The report provides a snapshot of the global therapeutic landscape of Rotavirus Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Rotavirus Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Rotavirus Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Rotavirus Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of…

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Rotavirus Infections Overview 7
Therapeutics Development 8
Pipeline Products for Rotavirus Infections - Overview 8
Pipeline Products for Rotavirus Infections - Comparative Analysis 9
Rotavirus Infections - Therapeutics under Development by Companies 10
Rotavirus Infections - Therapeutics under Investigation by Universities/Institutes 11
Rotavirus Infections - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Rotavirus Infections - Products under Development by Companies 15
Rotavirus Infections - Products under Investigation by Universities/Institutes 16
Rotavirus Infections - Companies Involved in Therapeutics Development 17
Beijing Minhai Biotechnology Co., Ltd 17
Biological E. Limited 18
CureVac GmbH 19
Medicago Inc. 20
Seek 21
Serum Institute of India Limited 22
Shantha Biotechnics Limited 23
Sinovac Biotech Ltd. 24
Takeda Pharmaceutical Company Limited 25
Rotavirus Infections - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
Antibody for Rotavirus Infections - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
BRV-TV - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Monoclonal Antibodies to Inhibit VP6 for Rotavirus Infections - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Oligonucleotide for Rotavirus Infection - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Protein to Activate Toll-Like Receptor 5 for Infectious Disease and Graft Versus Host Disease - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
rotavirus [serotypes G1, G2, G3, G4, G9] (pentavalent) vaccine - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
rotavirus (pentavalent) vaccine - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
rotavirus (tetravalent) vaccine - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
rotavirus [serotypes G1, G2, G3, G4, G9] (pentavalent) vaccine - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
rotavirus vaccine - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
rotavirus vaccine - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
rotavirus vaccine - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
rotavirus vaccine - Drug Profile…

For more information open Rotavirus Infections - Pipeline Review, H1 2015.


Original Article: Rotavirus Infections - Pipeline Review, H1 2015


More From BioPortfolio on "Rotavirus Infections - Pipeline Review, H1 2015"

Quick Search


Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...